Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119521) titled 'Hepatic arterial infusion Adebrelimab and FOLFOX chemotherapy plus Bevacizumab for advanced unresectable hepatocellular carcinoma: a prospective, single-arm clinical trial' on Feb. 28.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Second Affiliated Hospital of Guangzhou Medical University
Condition:
advanced unresectable hepatocellular carcinoma
Recruitment Status: Recruiting
Phase: 2
Date of First Enrollment: 2026-03-01
Target Sample Size: Intervention group:38;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=311692
Pu...